Dr. Das has over twenty-five years of teaching experience in the professional pharmacy and graduate programs in the USA and Canada. He has supervised a number of postdoctoral, graduate and undergraduate research students, and was the key faculty responsible for the revitalization of the graduate program and research infrastructure in pharmaceutical sciences at Butler University in 2004. His current research involves targeted delivery of siRNA and nano-composites for the treatment of cancer and neurodegenerative diseases. Dr. Das has over 150 research publications, review articles, patents, proceedings, conference presentations, and book chapters, is a recipient of multiple awards/honors, and has secured extramural research funding from NIH, PDA, and the pharmaceutical industry.
Dr. Das has been an active member of AACP since 1994, where he became an AACP Leadership Fellow (2005), and served as the chair-elect, chair and immediate past chair of the Teachers of Pharmaceutics Section (2006-09). From 2008-11, Dr. Das served as the founding chair and immediate past chair of the AACP Council of Sections, where he led the task of developing the mission and goals of the new council, and created various task forces supporting the missions of the AACP sections. He has also served on the AACP Board of Directors (2008-11), AACP Research & Graduate Affairs and the Bylaws and Policy Development Committees, along with various AACP Task Forces.
Dr. Das is also an active member of AAPS (since 1991) and CRS (Controlled Release Society, since 1987). He has served on many committees of the PDD/PPB and BIOTEC sections of AAPS. Since 2004, he has served on several study sections for the NIH - Center for Scientific Review, and continues to serve on the editorial boards of AJPE, Therapeutic Delivery and many journals in drug delivery and formulation development.
Strength Finder Top Five Attributes: LEARNER | STRATEGIC | ACHIEVER | FOCUS | INCLUDER
Specialties: Targeted delivery of anticancer drugs, modulation of MDR in cancer, delivery of siRNA, formulation development of poorly soluble drugs and stability studies of pharmaceuticals, biosimilar drugs.